钠-葡萄糖共转运蛋白2抑制剂药动学相互作用研究进展  

Research progress on pharmacokinetic interactions of sodium-glucose co-transporter 2 inhibitors

作　　者：邓艳茹 曹格溪 李颖[2] 李亚静 董占军[2] DENG Yanru;CAO Gexi;LI Ying;LI Yajing;DONG Zhanjun(Hebei Medical University College of Pharmacy,Shijiazhuang 050017,Hebei,China;Hebei General Hospital,Shijiazhuang 050051,Hebei,China)

机构地区：[1]河北医科大学药学院,河北石家庄050017 [2]河北省人民医院药学部,河北石家庄050051

出　　处：《中国临床药理学与治疗学》2025年第4期570-576,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：河北省自然科学基金项目(H2022307063)。

摘　　要：钠-葡萄糖共转运蛋白2(sodium-glucose co-transporter 2,SGLT2)抑制剂是一类新型口服降糖药物,具有降糖疗效确切、不易引起低血糖、心血管保护及肾脏获益等特点,近年来在临床上应用广泛,与其他药物联用的相互作用也逐渐受到关注。目前我国临床使用较为常见的SGLT2抑制剂包括卡格列净、达格列净、恩格列净、艾托格列净和恒格列净,该类药物主要经Ⅱ相代谢酶尿苷二磷酸葡萄糖醛酸转移酶(uridine diphosphate glucuronidase,UGT)代谢,并有多种转运体参与其在体内的处置过程。本文综述了上述不同SGLT2抑制剂的药动学特点以及与他汀类降脂药、抗肿瘤药、抗菌药、非甾体抗炎药、中药等多种药物的相互作用研究,以期促进临床SGLT2抑制剂的安全合理用药。Sodium-glucose co-transporter 2(SGLT2)inhibitors are a new class of oral hypoglycemic drugs with definite hypoglycemic effects,low risk of hypoglycemia,cardiovascular protection,and kidney benefits.In recent years,SGLT2 inhibitors have been widely used in clinical practice,and their interactions with other drugs have gradually attracted attention.The SGLT2 inhibitors commonly used in China's clinic include canagliflozin,dapagliflozin,empagliflozin,ertugliflozin and henagliflozin currently,they are mainly metabolized by the phaseⅡmetabolic enzyme uridine diphosphate glucuronosyltransferase(UGT),and various transporters are involved in the disposal of SGLT2 inhibitors in vivo.This article reviews the pharmacokinetic characteristics of different SGLT2 inhibitors mentioned above,as well as their pharmacokinetic interaction studies with various drugs such as statins,antineoplastic drugs,antimicrobials,nonsteroidal anti-inflammatory drugs and traditional Chinese medicine,in order to promote the safe and rational use of SGLT2 inhibitors in clinical practice.

关 键 词：钠-葡萄糖共转运蛋白2抑制剂 药代动力学 药物相互作用 尿苷二磷酸葡萄糖醛酸转移酶 转运体 

分 类 号：R969[医药卫生—药理学]